Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by stockman6767on Apr 16, 2019 11:34am
253 Views
Post# 29633276

RE:RE:RE:RE:The big question???

RE:RE:RE:RE:The big question???Responding to my own question - The NR from PLI gives the details on the waarants repricing and how many they are. The total comes to 168,735,398 8 year warrants at the 0,01521 ex price.in addition to the share from the debt conversion.

Details of the Warrant Repricing
SALP currently owns the following Warrants:
  • 1,000,000 Warrants, each of which entitles SALP to acquire one Common Share upon the payment of an exercise price equal to $0.52 per Warrant (“Warrants 1”);
  • 20,276,595 Warrants, each of which entitles SALP to acquire one Common Share upon the payment of an aggregate exercise price equal to $15,653,138 (“Warrants 2”);
  • 128,056,881 Warrants, each of which entitles SALP to acquire one Common Share upon the payment of an exercise price equal to $1.00 per Warrant (“Warrants 8”); and
  • 19,401,832 Warrants, each of which entitles SALP to acquire one Series A Preferred Share in the capital of Prometic upon the payment of an exercise price equal to $0.15636 per Warrant (“Warrants 9”).
Concurrently with the Debt Conversion (i) the exercise price of the Warrants 1, 2, 8 and 9, will be adjusted to the Transaction Price, (ii) Warrant 9 will become exercisable for Common Shares instead of Series A Preferred Shares and (iii) Warrants 1, 2, 8 and 9 will be consolidated into new Common Share purchase warrants. These changes will be reflected by the issuance of new “Warrant 10” with an eight year term.

 
Bullboard Posts